Elanco Animal Health Incorporated (ELAN)

Market Cap	6.37B
Revenue (ttm)	4.37B
Net Income (ttm)	-1.30B
Shares Out	494.18M
EPS (ttm)	-2.65
PE Ratio	n/a
Forward PE	13.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,388,964
Open	12.98
Previous Close	12.82
Day's Range	12.77 - 13.14
52-Week Range	8.52 - 18.80
Beta	1.42
Analysts	Buy
Price Target	17.50 (+35.66%)
Earnings Date	Aug 8, 2024

About ELAN

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticid...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 20, 2018
• Employees: 9,800
• Stock Exchange: NYSE
• Ticker Symbol: ELAN

Financial Performance

In 2023, ELAN's revenue was $4.42 billion, an increase of 0.14% compared to the previous year's $4.41 billion. Losses were -$1.23 billion, 1478.2% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ELAN stock is "Buy." The 12-month stock price forecast is $17.5, which is an increase of 35.66% from the latest price.

Price Target

$17.5

(35.66% upside)

Analyst Consensus: Buy